Romosozumab Treatment in Postmenopausal Women with Osteoporosis, PMID: 27641143
Romosozumab for the treatment of osteoporosis, PMID: 28064540
Romosozumab: A Review in Postmenopausal Osteoporosis, PMID: 32909197
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis, PMID: 28892457
Romosozumab and Sequential Therapy in Postmenopausal Osteoporosis, PMID: 32600508
Romosozumab for the treatment of osteoporosis, PMID: 30775535
Romosozumab: a Review of Efficacy, Safety, and Cardiovascular Risk, PMID: 33409990
Romosozumab: A first-in-class sclerostin inhibitor for osteoporosis, PMID: 32880646
Romosozumab in postmenopausal women with low bone mineral density, PMID: 24382002
A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures, PMID: 31977817
Efficacy and safety of Romosozumab in treatment for low bone mineral density: a systematic review and meta-analysis, PMID: 32385757
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial, PMID: 28755782
Romosozumab: First Global Approval, PMID: 30805895
Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab, PMID: 31628490
Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study, PMID: 29694685
Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study, PMID: 32047951
Cardiovascular Outcomes of Romosozumab and Protective Role of Alendronate, PMID: 31242037
Romosozumab: A Novel Injectable Sclerostin Inhibitor With Anabolic and Antiresorptive Effects for Osteoporosis, PMID: 32862655
A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis, PMID: 29931216
Bone-Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment, PMID: 31233639
One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study, PMID: 30508316
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis, PMID: 31678488
FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab, PMID: 29573473
Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass, PMID: 27487526
Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis, PMID: 32777516
Romosozumab in the treatment of osteoporosis, PMID: 32752907
Profile of romosozumab and its potential in the management of osteoporosis, PMID: 28458516
A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab, PMID: 32623487
Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis, PMID: 31626995
Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial, PMID: 33057807
Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial, PMID: 31707465
Romosozumab (sclerostin monoclonal antibody) for the treatment of osteoporosis in postmenopausal women: A review, PMID: 31922699
Osteoporosis: now and the future, PMID: 21450337
Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension, PMID: 31168657
Osteoporosis treatment: recent developments and ongoing challenges, PMID: 28689769
Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study, PMID: 32979066
Osteoporosis in Older Adults, PMID: 32773051
Antibodies to watch in 2020, PMID: 31847708
Romosozumab-aqqg, upadacitinib, and risankizumab-rzaa, PMID: 31735342
Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation, PMID: 32588816
[The sequential therapy of romosozumab followed by denosumab for osteoporosis], PMID: 30814382
Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture: A Randomized Phase-2 Study, PMID: 32358413
Romosozumab, clinical trials, and real-world care of patients with osteoporosis, PMID: 32953774
Safety of Romosozumab in Osteoporotic Men and Postmenopausal Women: A Meta-Analysis and Systematic Review, PMID: 32195618
Unmasking romosozumab, PMID: 28213619
Romosozumab (Evenity) for postmenopausal osteoporosis, PMID: 31170119
Romosozumab for osteoporosis, PMID: 34211250
Romosozumab, PMID: 34251779
Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report, PMID: 32548215
Carcinogenicity risk assessment of romosozumab: A review of scientific weight-of-evidence and findings in a rat lifetime pharmacology study, PMID: 27569204
For research use only. Not for human or drug use.
